51 placebo-treated patients; they found that the insulin releasing drug liraglutide, administered at 1.8 mg/d for 26 weeks, had virtually no effect on FDG uptake in the carotids and ascending aorta, albeit an exploratory analysis suggested a borderline significant effect in individuals with a history of CVD [ 46 ].
1
—
—